High intensity focused ultrasound ablation

A new therapeutic option for solid tumors

Franco Orsi, Paolo Arnone, Wenzhi Chen, Lian Zhang

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Surgery has been the standard of care in selected cases with solid tumors. However, a majority of patients are unable to undergo surgical resection because of the tumor sites, advanced stages, or poor general condition. High intensity focused ultrasound (HIFU) is a novel non-invasive technique that is capable of producing coagulative necrosis at a precise focal point within the body, without harming overlying and adjacent structures even within the path of the beam. Diagnostic ultrasound was the first imaging modality used for guiding HIFU ablation in the 1990s. Over the last decade, thousands of patients with uterine fibroids, liver cancer, breast cancer, pancreatic cancer, bone tumors, renal cancer have been treated with ultrasound imaging-guided HIFU (USgHIFU) worldwide. This USgHIFU system [Chongqing Haifu (HIFU) Tech Co., Ltd., Chongqing, China] was first equipped in Asia, now in Europe. Several research groups have demonstrated that HIFU is safe and effective in treating human solid tumors. In 2004, the magnetic resonance guided focused ultrasound surgery (MRgFUS) was approved by the United States Food and Drug Administration (FDA) for clinical treatments of uterine fibroids. We conclude that HIFU offers patients another choice when no other treatment available or when patients refused surgical operation. This technique may play a key role in future clinical practice.

Original languageEnglish
Pages (from-to)414-420
Number of pages7
JournalJournal of Cancer Research and Therapeutics
Volume6
Issue number4
DOIs
Publication statusPublished - Oct 2010

Fingerprint

High-Intensity Focused Ultrasound Ablation
Ultrasonography
Leiomyoma
Neoplasms
Breast Neoplasms
Bone Neoplasms
Kidney Neoplasms
United States Food and Drug Administration
Therapeutics
Standard of Care
Liver Neoplasms
Pancreatic Neoplasms
China
Necrosis
Magnetic Resonance Spectroscopy
Research

Keywords

  • cancer
  • High intensity focused ultrasound
  • treatment

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

High intensity focused ultrasound ablation : A new therapeutic option for solid tumors. / Orsi, Franco; Arnone, Paolo; Chen, Wenzhi; Zhang, Lian.

In: Journal of Cancer Research and Therapeutics, Vol. 6, No. 4, 10.2010, p. 414-420.

Research output: Contribution to journalArticle

@article{58ec7018891a47e3878a6f7f242434ef,
title = "High intensity focused ultrasound ablation: A new therapeutic option for solid tumors",
abstract = "Surgery has been the standard of care in selected cases with solid tumors. However, a majority of patients are unable to undergo surgical resection because of the tumor sites, advanced stages, or poor general condition. High intensity focused ultrasound (HIFU) is a novel non-invasive technique that is capable of producing coagulative necrosis at a precise focal point within the body, without harming overlying and adjacent structures even within the path of the beam. Diagnostic ultrasound was the first imaging modality used for guiding HIFU ablation in the 1990s. Over the last decade, thousands of patients with uterine fibroids, liver cancer, breast cancer, pancreatic cancer, bone tumors, renal cancer have been treated with ultrasound imaging-guided HIFU (USgHIFU) worldwide. This USgHIFU system [Chongqing Haifu (HIFU) Tech Co., Ltd., Chongqing, China] was first equipped in Asia, now in Europe. Several research groups have demonstrated that HIFU is safe and effective in treating human solid tumors. In 2004, the magnetic resonance guided focused ultrasound surgery (MRgFUS) was approved by the United States Food and Drug Administration (FDA) for clinical treatments of uterine fibroids. We conclude that HIFU offers patients another choice when no other treatment available or when patients refused surgical operation. This technique may play a key role in future clinical practice.",
keywords = "cancer, High intensity focused ultrasound, treatment",
author = "Franco Orsi and Paolo Arnone and Wenzhi Chen and Lian Zhang",
year = "2010",
month = "10",
doi = "10.4103/0973-1482.77064",
language = "English",
volume = "6",
pages = "414--420",
journal = "Journal of Cancer Research and Therapeutics",
issn = "0973-1482",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "4",

}

TY - JOUR

T1 - High intensity focused ultrasound ablation

T2 - A new therapeutic option for solid tumors

AU - Orsi, Franco

AU - Arnone, Paolo

AU - Chen, Wenzhi

AU - Zhang, Lian

PY - 2010/10

Y1 - 2010/10

N2 - Surgery has been the standard of care in selected cases with solid tumors. However, a majority of patients are unable to undergo surgical resection because of the tumor sites, advanced stages, or poor general condition. High intensity focused ultrasound (HIFU) is a novel non-invasive technique that is capable of producing coagulative necrosis at a precise focal point within the body, without harming overlying and adjacent structures even within the path of the beam. Diagnostic ultrasound was the first imaging modality used for guiding HIFU ablation in the 1990s. Over the last decade, thousands of patients with uterine fibroids, liver cancer, breast cancer, pancreatic cancer, bone tumors, renal cancer have been treated with ultrasound imaging-guided HIFU (USgHIFU) worldwide. This USgHIFU system [Chongqing Haifu (HIFU) Tech Co., Ltd., Chongqing, China] was first equipped in Asia, now in Europe. Several research groups have demonstrated that HIFU is safe and effective in treating human solid tumors. In 2004, the magnetic resonance guided focused ultrasound surgery (MRgFUS) was approved by the United States Food and Drug Administration (FDA) for clinical treatments of uterine fibroids. We conclude that HIFU offers patients another choice when no other treatment available or when patients refused surgical operation. This technique may play a key role in future clinical practice.

AB - Surgery has been the standard of care in selected cases with solid tumors. However, a majority of patients are unable to undergo surgical resection because of the tumor sites, advanced stages, or poor general condition. High intensity focused ultrasound (HIFU) is a novel non-invasive technique that is capable of producing coagulative necrosis at a precise focal point within the body, without harming overlying and adjacent structures even within the path of the beam. Diagnostic ultrasound was the first imaging modality used for guiding HIFU ablation in the 1990s. Over the last decade, thousands of patients with uterine fibroids, liver cancer, breast cancer, pancreatic cancer, bone tumors, renal cancer have been treated with ultrasound imaging-guided HIFU (USgHIFU) worldwide. This USgHIFU system [Chongqing Haifu (HIFU) Tech Co., Ltd., Chongqing, China] was first equipped in Asia, now in Europe. Several research groups have demonstrated that HIFU is safe and effective in treating human solid tumors. In 2004, the magnetic resonance guided focused ultrasound surgery (MRgFUS) was approved by the United States Food and Drug Administration (FDA) for clinical treatments of uterine fibroids. We conclude that HIFU offers patients another choice when no other treatment available or when patients refused surgical operation. This technique may play a key role in future clinical practice.

KW - cancer

KW - High intensity focused ultrasound

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=79952433984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952433984&partnerID=8YFLogxK

U2 - 10.4103/0973-1482.77064

DO - 10.4103/0973-1482.77064

M3 - Article

VL - 6

SP - 414

EP - 420

JO - Journal of Cancer Research and Therapeutics

JF - Journal of Cancer Research and Therapeutics

SN - 0973-1482

IS - 4

ER -